Selective loss of nigral dopamine neurons induced by overexpression of truncated human α-synuclein in mice

Neurobiology of Aging

Volumn 29, Issue 4, 2008, Pages 574-585

  Wakamatsu, Masaki ^a   Ishii, Aiko ^a   Iwata, Shingo ^a   Sakagami, Junko ^a   Ukai, Yuriko ^a   Ono, Mieko ^a   Kanbe, Daiji ^a   Muramatsu, Shin ichi ^b   Kobayashi, Kazuto ^c   Iwatsubo, Takeshi ^d   Yoshimoto, Makoto ^a  

^a TAISHO PHARMACEUTICAL CO LTD   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

^c FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

Synuclein; Animal model; Dopamine neuron; Parkinson's disease; Transgenic mouse; Tyrosine hydroxylase

Indexed keywords

ALPHA SYNUCLEIN; LEVODOPA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; EMBRYO DEVELOPMENT; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LEWY BODY; LOCOMOTION; MOUSE; NERVE ENDING; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ALPHA-SYNUCLEIN; ANIMALS; CELL COUNT; DOPAMINE; GENE EXPRESSION REGULATION; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEURONS; RATS; SEQUENCE DELETION; SUBSTANTIA NIGRA;

EID: 39749196233     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2006.11.017     Document Type: Article

References (46)

1. Albani D., Peverelli E., Rametta R., Batelli S., Veschini L., Negro A., and Forloni G. Protective effect of TAT-delivered alpha-synuclein: relevance of the C-terminal domain and involvement of HSP70. Faseb J. 18 (2004) 1713-1715
2. Arawaka S., Saito Y., Murayama S., and Mori H. Lewy body in neurodegeneration with brain iron accumulation type 1 is immunoreactive for alpha-synuclein. Neurology 51 3 (1998) 887-889
3. Arima K., Ueda K., Sunohara N., Hirai S., Izumiyama Y., Tonozuka-Uehara H., and Kawai M. Immunoelectron-microscopic demonstration of NACP/alpha-synuclein-epitopes on the filamentous component of Lewy bodies in Parkinson's disease and in dementia with Lewy bodies. Brain Res. 808 1 (1998) 93-100
4. Baba M., Nakajo S., Tu P.H., Tomita T., Nakaya K., Lee V.M., Trojanowski J.Q., and Iwatsubo T. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am. J. Pathol. 152 4 (1998) 879-884
5. Campbell B.C., McLean C.A., Culvenor J.G., Gai W.P., Blumbergs P.C., Jakala P., Beyreuther K., Masters C.L., and Li Q.X. The solubility of alpha-synuclein in multiple system atrophy differs from that of dementia with Lewy bodies and Parkinson's disease. J. Neurochem. 76 1 (2001) 87-96
6. Chen L., and Feany M.B. Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat. Neurosci. 8 5 (2005) 657-663
7. Crowther R.A., Jakes R., Spillantini M.G., and Goedert M. Synthetic filaments assembled from C-terminally truncated alpha-synuclein. FEBS Lett. 436 3 (1998) 309-312
8. Du H.N., Tang L., Luo X.Y., Li H.T., Hu J., Zhou J.W., and Hu H.Y. A peptide motif consisting of glycine, alanine, and valine is required for the fibrillization and cytotoxicity of human alpha-synuclein. Biochemistry 42 29 (2003) 8870-8878
9. Fujiwara H., Hasegawa M., Dohmae N., Kawashima A., Masliah E., Goldberg M.S., Shen J., Takio K., and Iwatsubo T. alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell. Biol. 4 2 (2002) 160-164
10. Giasson B.I., Duda J.E., Quinn S.M., Zhang B., Trojanowski J.Q., and Lee V.M. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron 34 4 (2002) 521-533
11. Hogan B., Beddington R., Costantini F., and Lacy E. Manipulating the Mouse Embryo. Second ed. (1994), Cold Spring Harbor Laboratory Press, Plainview
12. Iwai A., Masliah E., Yoshimoto M., Ge N., Flanagan L., de Silva H.A., Kittel A., and Saitoh T. The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 14 2 (1995) 467-475
13. Iwawaki T., Kohno K., and Kobayashi K. Identification of a potential nurr1 response element that activates the tyrosine hydroxylase gene promoter in cultured cells. Biochem. Biophys. Res. Commun. 274 3 (2000) 590-595
14. Jakes R., Crowther R.A., Lee V.M., Trojanowski J.Q., Iwatsubo T., and Goedert M. Epitope mapping of LB509, a monoclonal antibody directed against human alpha-synuclein. Neurosci. Lett. 269 1 (1999) 13-16
15. Kahle P.J., Neumann M., Ozmen L., Muller V., Jacobsen H., Schindzielorz A., Okochi M., Leimer U., van Der Putten H., Probst A., Kremmer E., Kretzschmar H.A., and Haass C. Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha-synuclein in human and transgenic mouse brain. J. Neurosci. 20 17 (2000) 6365-6373
16. Kanda S., Bishop J.F., Eglitis M.A., Yang Y., and Mouradian M.M. Enhanced vulnerability to oxidative stress by alpha-synuclein mutations and C-terminal truncation. Neuroscience 97 2 (2000) 279-284
17. Kaur S., and Starr M.S. Antiparkinsonian action of dextromethorphan in the reserpine-treated mouse. Eur. J. Pharmacol. 280 2 (1995) 159-166
18. Kobayashi K., Sasaoka T., Morita S., Nagatsu I., Iguchi A., Kurosawa Y., Fujita K., Nomura T., Kimura M., Katsuki M., and Nagatsu T. Genetic alteration of catecholamine specificity in transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 89 5 (1992) 1631-1635
19. Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S., Przuntek H., Epplen J.T., Schols L., and Riess O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 18 2 (1998) 106-108
20. Lee M.K., Stirling W., Xu Y., Xu X., Qui D., Mandir A.S., Dawson T.M., Copeland N.G., Jenkins N.A., and Price D.L. Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 → Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 99 13 (2002) 8968-8973
21. Li W., West N., Colla E., Pletnikova O., Troncoso J.C., Marsh L., Dawson T.M., Jakala P., Hartmann T., Price D.L., and Lee M.K. Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proc. Natl. Acad. Sci. U.S.A. 102 6 (2005) 2162-2167
22. Liu C.W., Giasson B.I., Lewis K.A., Lee V.M., Demartino G.N., and Thomas P.J. A precipitating role for truncated alpha-synuclein and the proteasome in alpha-synuclein aggregation: implications for pathogenesis of Parkinson disease. J. Biol. Chem. 280 24 (2005) 22670-22678
23. Masliah E., Rockenstein E., Veinbergs I., Mallory M., Hashimoto M., Takeda A., Sagara Y., Sisk A., and Mucke L. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 287 5456 (2000) 1265-1269
24. Matsuoka Y., Vila M., Lincoln S., McCormack A., Picciano M., LaFrancois J., Yu X., Dickson D., Langston W.J., McGowan E., Farrer M., Hardy J., Duff K., Przedborski S., and Di Monte D.A. Lack of nigral pathology in transgenic mice expressing human alpha-synuclein driven by the tyrosine hydroxylase promoter. Neurobiol. Dis. 8 3 (2001) 535-539
25. Min N., Joh T.H., Kim K.S., Peng C., and Son J.H. 5′ upstream DNA sequence of the rat tyrosine hydroxylase gene directs high-level and tissue-specific expression to catecholaminergic neurons in the central nervous system of transgenic mice. Brain Res. Mol. Brain Res. 27 2 (1994) 281-289
26. Murray I.V., Giasson B.I., Quinn S.M., Koppaka V., Axelsen P.H., Ischiropoulos H., Trojanowski J.Q., and Lee V.M. Role of alpha-synuclein carboxy-terminus on fibril formation in vitro. Biochemistry 42 28 (2003) 8530-8540
27. Neumann M., Kahle P.J., Giasson B.I., Ozmen L., Borroni E., Spooren W., Muller V., Odoy S., Fujiwara H., Hasegawa M., Iwatsubo T., Trojanowski J.Q., Kretzschmar H.A., and Haass C. Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. J. Clin. Invest. 110 10 (2002) 1429-1439
28. Okochi M., Walter J., Koyama A., Nakajo S., Baba M., Iwatsubo T., Meijer L., Kahle P.J., and Haass C. Constitutive phosphorylation of the Parkinson's disease associated alpha-synuclein. J. Biol. Chem. 275 1 (2000) 390-397
29. Paxinos G., and Franklin K.B.J. The Mouse Brain in Stereotaxic Coordinates. Second ed. (2001), Academic Press, San Diego
30. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L.I., and Nussbaum R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276 5321 (1997) 2045-2047
31. Pronin A.N., Morris A.J., Surguchov A., and Benovic J.L. Synucleins are a novel class of substrates for G protein-coupled receptor kinases. J. Biol. Chem. 275 34 (2000) 26515-26522
32. Richfield E.K., Thiruchelvam M.J., Cory-Slechta D.A., Wuertzer C., Gainetdinov R.R., Caron M.G., Di Monte D.A., and Federoff H.J. Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice. Exp. Neurol. 175 1 (2002) 35-48
33. Singleton A.B., Farrer M., Johnson J., Singleton A., Hague S., Kachergus J., Hulihan M., Peuralinna T., Dutra A., Nussbaum R., Lincoln S., Crawley A., Hanson M., Maraganore D., Adler C., Cookson M.R., Muenter M., Baptista M., Miller D., Blancato J., Hardy J., and Gwinn-Hardy K. alpha-Synuclein locus triplication causes Parkinson's disease. Science 302 5646 (2003) 841
34. Sotnikova T.D., Beaulieu J.M., Barak L.S., Wetsel W.C., Caron M.G., and Gainetdinov R.R. Dopamine-independent locomotor actions of amphetamines in a novel acute mouse model of Parkinson disease. PLoS Biol. 3 8 (2005) e271
35. Spillantini M.G., Crowther R.A., Jakes R., Hasegawa M., and Goedert M. Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc. Natl. Acad. Sci. U.S.A. 95 11 (1998) 6469-6473
36. Takeda A., Mallory M., Sundsmo M., Honer W., Hansen L., and Masliah E. Abnormal accumulation of NACP/alpha-synuclein in neurodegenerative disorders. Am. J. Pathol. 152 2 (1998) 367-372
37. Tillerson J.L., Caudle W.M., Reveron M.E., and Miller G.W. Detection of behavioral impairments correlated to neurochemical deficits in mice treated with moderate doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Exp. Neurol. 178 1 (2002) 80-90
38. Tofaris G.K., Garcia Reitbock P., Humby T., Lambourne S.L., O'Connell M., Ghetti B., Gossage H., Emson P.C., Wilkinson L.S., Goedert M., and Spillantini M.G. Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human alpha-synuclein(1-120): implications for Lewy body disorders. J. Neurosci. 26 15 (2006) 3942-3950
39. Tofaris G.K., Razzaq A., Ghetti B., Lilley K.S., and Spillantini M.G. Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function. J. Biol. Chem. 278 45 (2003) 44405-44411
40. Ueda K., Fukushima H., Masliah E., Xia Y., Iwai A., Yoshimoto M., Otero D.A., Kondo J., Ihara Y., and Saitoh T. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 90 23 (1993) 11282-11286
41. van der Putten H., Wiederhold K.H., Probst A., Barbieri S., Mistl C., Danner S., Kauffmann S., Hofele K., Spooren W.P., Ruegg M.A., Lin S., Caroni P., Sommer B., Tolnay M., and Bilbe G. Neuropathology in mice expressing human alpha-synuclein. J. Neurosci. 20 16 (2000) 6021-6029
42. Vila M., Jackson-Lewis V., Guegan C., Wu D.C., Teismann P., Choi D.K., Tieu K., and Przedborski S. The role of glial cells in Parkinson's disease. Curr. Opin. Neurol. 14 4 (2001) 483-489
43. Vincent S., Marty L., and Fort P. S26 ribosomal protein RNA: an invariant control for gene regulation experiments in eucaryotic cells and tissues. Nucleic Acids Res. 21 6 (1993) 1498
44. Wakabayashi K., Hayashi S., Yoshimoto M., Kudo H., and Takahashi H. NACP/alpha-synuclein-positive filamentous inclusions in astrocytes and oligodendrocytes of Parkinson's disease brains. Acta Neuropathol. (Berl.) 99 1 (2000) 14-20
45. Wakabayashi K., Matsumoto K., Takayama K., Yoshimoto M., and Takahashi H. NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease. Neurosci. Lett. 239 1 (1997) 45-48
46. Zarranz J.J., Alegre J., Gomez-Esteban J.C., Lezcano E., Ros R., Ampuero I., Vidal L., Hoenicka J., Rodriguez O., Atares B., Llorens V., Gomez Tortosa E., del Ser T., Munoz D.G., and de Yebenes J.G. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55 2 (2004) 164-173